Glioblastoma Multiforme (GBM) Market

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults. <br><br>As per the Delveinsight, the market size of Glioblastoma Multiforme in the 7MM (i.e United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) was USD 1,005 Million in 2017. <br><br>The total diagnosed incident population of Glioblastoma Multiforme in seven major markets was 28,259 in 2017. It is observed that GBM is more prevalent among males than females in 7MM. <br><br>Robust pipeline activity, upcoming launches and approval, improved treatment deliverance, emergence of immunotherapies, advancements in genomics and proteomics, low cost of treatment, interventions that can cross the blood-brain-barrier are some of the key driver for the Glioblastoma Multiforme Market. <br><br>The key companies in the Glioblastoma Multiforme market includes VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals. <br><br>Source: Glioblastoma Multiforme (GBM) Market<br><br>For more information on Glioblastoma Multiforme (GBM) Market, visit:<br>https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market<br>

DelveInsight + Follow